Locations:
Search IconSearch
September 22, 2016/Cancer

Managing Lynch and FAP: A Balance Between Cancer Prevention and Quality of Life

Action items for managing these complex patients

16-DDI-2083-Lynch-FAP-CQD-650×450

By James M. Church, MD

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

For people with inherited colorectal cancer predisposition syndromes and their families, the goals of cancer prevention and treatment should be balanced with the preservation of quality of life.

The stakes are high because these patients are often relatively young when they develop multifocal neoplasia, and critical management decisions involve both patients and their as-yet unaffected family members.

At Cleveland Clinic, we monitor both patients and family members very closely and avoid surgery if possible. If colectomy is required, we approach it in way that preserves function and quality of life.

Lynch syndrome and familial adenomatous polyposis (FAP) are the most common and best known of the dominantly inherited colorectal cancer syndromes. Both arise from germline mutations that result in destabilization and deregulation of cell growth. And in both syndromes, there are critical questions involving the type and timing of surgery.

Lynch syndrome: Extensive surgery versus standard surgery and colonoscopy

Patients with Lynch syndrome have a mutation in their DNA that causes repair of DNA mismatches to fail. This creates mutations in multiple genes that predispose to the development of colorectal, endometrial (uterine) and other cancers at an early age.

Patients and families with Lynch syndrome can be identified by testing of their tumors for evidence of the mutation or by family history, where the dominant inheritance creates a typical pattern of multiple cancers in young (< 50 years) relatives.

In the best possible scenario, a diagnosis is made early in a patient with cancer due to Lynch syndrome via testing of the cancer seen during colonoscopy. This allows the surgeon to plan surgery to minimize the risk of further colon cancer. Total colectomy and ileorectal anastomosis can be performed safely, without a stoma, and with an acceptable bowel function and a good quality of life.

Advertisement

Unfortunately, the more common scenario is a standard cancer operation, with testing of the cancer performed only after it has been removed. Then, if the patient turns out to have Lynch syndrome, the options are either to rely on annual colonoscopy to prevent further cancers or to perform reoperation to remove the rest of the colon. Most patients choose annual colonoscopy.

For affected family members with as-yet normal colons, we generally don’t recommend primary prophylactic colectomy unless the individual is particularly worried about developing colorectal cancer and wants the surgery, or the family has a particularly aggressive disease phenotype. In most cases, we instead recommend colonoscopy every one to two years.

Action item:

When gastroenterologists see a colorectal cancer in a young patient or a patient with a strong family history of colorectal cancer, they should request immunohistochemistry testing of the tumor for evidence of loss of expression of a DNA mismatch repair protein, or microsatellite instability testing. A positive test suggests the possibility of Lynch syndrome and demands further investigation. A negative test largely rules it out.

Familial adenomatous polyposis: Wait to operate

While FAP is also a dominantly inherited form of colorectal cancer, it differs from Lynch in three important ways:

  1. The risk of colorectal cancer is higher and cancer occurs at younger ages.
  2. Hundreds to thousands of polyps are an obvious indication of the syndrome, and therefore genetic testing is not so critical to make the diagnosis.
  3. The rectum is often removed, with the operation of ileal pouch anal anastomosis among the list of alternative surgeries.

Advertisement

The surgical approach to FAP revolves around two decisions: When to do the operation and what operation to do. Because of their high risk of cancer, immediate surgery is necessary for patients who are symptomatic or who have profuse polyposis (1,000 or more adenomas).

But for most others, surgery can be scheduled at a time in the patient’s life — ideally during adulthood — when they are capable of dealing mentally with the stresses involved, when academic and social plans will not be interrupted, and when financial considerations are favorable. At Cleveland Clinic, we monitor these patients’ colons annually, paying attention to the number and size of polyps.

When the risk starts to climb, we intervene with the most conservative procedure possible to reduce the risk of cancer while minimizing complications and allowing better bowel function. We’re also increasingly using minimally invasive techniques that have helped to reduce pain and disability.

For patients with mild FAP, the standard operation is a total colectomy with ileorectal anastomosis. This can be done laparoscopically, with no stoma, minimal hospital stay, little time off work and school, and a small impact on quality of life.

However, severe FAP involving the rectum generally requires pouch surgery, which is more major and often involves a temporary ileostomy, significant changes in bowel habit, longer recovery and greater risk for complications. There is a potential for creating severe problems in the lives of basically asymptomatic patients, so it is essential that pouch surgery be done in a hospital with proven expertise and experience in this demanding procedure.

Advertisement

Action item:

Occurring in just about 1 in every 8,000 births, FAP is not a condition gastroenterologists see often. But when they do, referral to a specialty center is highly recommended.

Read Dr. Church’s article on Controversies in the surgery of patients with familial adenomatous polyposis and Lynch syndrome in the July 2016 issue of Familial Cancer.

Advertisement

Related Articles

cells with idiopathic multicentric Castleman Disease
February 20, 2025/Cancer/News & Insight
Study Offers New Insights into Idiopathic Multicentric Castleman Disease

Highlighting treatment gaps and challenges in the management of rare condition

CAR T-cell therapy
February 18, 2025/Cancer/News & Insight
Top Myths About CAR T-Cell Therapy for Multiple Myeloma

Explaining common misconceptions about chimeric antigen receptor therapy

Silhouettes of man and woman
February 7, 2025/Cancer/News & Insight
Pharmacokinetics of Many Anticancer Drugs Differ Among Sexes

Slower drug elimination from the body among females may impact safety and efficacy

Mobile mammography van
February 6, 2025/Cancer/News & Insight
Increasing Breast Cancer Screening in Women Experiencing Homelessness

Partnerships with local social service agencies key to program success

Eye melanoma
February 4, 2025/Cancer
Novel Neoadjuvant Treatment Trial for Uveal Melanoma

Oral medication may have potential to preserve vision and shrink tumors prior to surgery or radiation

Specialty pharmacy
January 24, 2025/Cancer/News & Insight
Researchers Seek Actionable Ways to Reduce Time to Treatment of Multiple Myeloma

Study examines modifiable determinants of health disparities

Woman wearing pink scarf
January 17, 2025/Cancer/News & Insight
Exceptional Responders to Metastatic Breast Cancer Treatment Characterized

Findings may guide future research and personalized treatments

Tumor-Infiltrating Lymphocytes (TIL) therapy
January 6, 2025/Cancer/News & Insight
Tumor-Infiltrating Lymphocytes Therapy Now Available for Treating Unresectable or Metastatic Melanoma

Cleveland Clinic Cancer Institute among select group of centers to administer highly personalized treatment

Ad